MannKind to Report Third Quarter Financial Results and Host Conference Call on November 5, 2026
MannKind (Nasdaq: MNKD) will report third quarter 2026 financial results after market close on November 5, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
MannKind (Nasdaq: MNKD) will report third quarter 2026 financial results after market close on November 5, 2026. Management will host a conference call at 4:30 p.m. Eastern Time that day to discuss results and provide a business update. A live webcast will be available in the Events & Presentations section of its Investor Relations website, with a replay available there for approximately 90 days.
Key Figures
- Results date
- November 5, 2026
- Third-quarter 2026 results scheduled after market close
AI-generated analysis. How Rhea-AI works. Not financial advice.
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced today that it will report third quarter 2026 financial results after market close on Thursday, November 5, 2026.
MannKind’s management team will host a conference call at 4:30 p.m. Eastern Time on Thursday, November 5, 2026, to discuss the financial results and provide a business update.
A live webcast of the conference call will be available in the Events & Presentations section of MannKind’s Investor Relations website. A replay will remain available in the same location for approximately 90 days following the conference call.
About MannKind
MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.
With deep expertise in drug-device combinations, MannKind aims to deliver therapies designed to fit seamlessly into daily life.
Learn more at mannkindcorp.com.
Contacts: Investor Relations Kate Miranda Email: ir@mnkd.com Media Relations Christie Iacangelo Email: media@mnkd.com